News Archives - Page 8 of 30

MondayJul 21, 2025 11:26 am

AINewsBreaks – ONAR Holding Corp. (OTCQB: ONAR) Appoints Former MDC CEO Scott Kauffman as Board Chairman

ONAR (OTCQB: ONAR) has appointed Scott Kauffman, former Chairman and CEO of MDC Partners, as Chairman of its Board of Directors, signaling a new phase of growth and M&A activity. Kauffman brings over 30 years of leadership in marketing, media, and digital innovation, including leading MDC through its merger with Stagwell Inc. (NASDAQ: STGW). His appointment aligns with ONAR’s strategy to scale its marketing tech platform for mid-sized brands and expand its global agency network through both organic growth and acquisitions. To view the full interview, visit https://ibn.fm/IqtSw About ONAR  ONAR (OTCQB: ONAR) is a leading marketing technology company and…

MondayJul 21, 2025 9:40 am

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern’s RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern’s strategic partnership potential. To view…

MondayJul 21, 2025 9:30 am

AINewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Integrates AI Object Detection with U.S. Army Recon Drones

Safe Pro Group (NASDAQ: SPAI) has integrated its patented AI object detection models into drone platforms selected for the U.S. Army’s Short Range Reconnaissance Program of Record, aiming to enhance explosive threat detection and ISR capabilities. The technology, battle-tested in Ukraine, enables rapid identification of over 150 threat types and is scalable across real-time and cloud-based platforms. Safe Pro is now engaging with DoD stakeholders and integrating its SPOTD system into the ATAK ecosystem to support large-scale force protection under increased defense spending authorized by the OBBBA. To view the full press release, visit https://ibn.fm/dT9Ld About Safe Pro Group Inc.…

FridayJul 18, 2025 12:18 pm

AINewsBreaks – ONAR Holding Corporation (OTCQB: ONAR) Appoints AI and Cybersecurity Leader Mark Gazit to Board

ONAR (OTCQB: ONAR), a leading marketing technology company and agency network, has appointed Mark Gazit to its Board of Directors. Gazit, renowned for his work in AI and cybersecurity, co-founded ThetaRay and served as its CEO for a decade, scaling it into a global leader in financial crime detection. ONAR CEO Claude Zdanow said Gazit’s expertise will help accelerate the company’s next phase of growth. Gazit praised ONAR’s AI-driven approach to middle-market marketing, citing its innovation and agency network expansion as key differentiators. To view the full press release, visit https://ibn.fm/XH2uh About ONAR ONAR (OTCQB: ONAR) is a leading marketing…

FridayJul 18, 2025 11:43 am

AINewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Expands Indo-Pacific Defense Role With New U.S. Government Contractor Order

Safe Pro Group (NASDAQ: SPAI), an AI-driven defense and security solutions provider, received a new order from a U.S. Government Contractor supporting Department of State demining operations in the Indo-Asia Pacific region. Scheduled for Q3 2025 delivery, the order includes ballistic and Explosive Ordnance Disposal (EOD) protective equipment. Safe Pro will also deploy and demonstrate its proprietary SpotlightAI(TM) drone-based computer vision platform for landmine detection. Following passage of the $30 billion One Big Beautiful Bill Act (OBBBA), the Company is expanding to support the U.S. Indo-Pacific Command (USINDOPACOM) and plans broader integration of its SPOTD threat detection technology with military…

ThursdayJul 17, 2025 10:05 am

AINewsBreaks – ONAR Holding Corp. (OTCQB: ONAR) to Acquire Retina.ai, Bolstering Predictive Marketing Capabilities

ONAR (OTCQB: ONAR), a marketing-technology firm and agency network, has signed a definitive agreement to acquire Retina.ai, a leading AI marketing intelligence platform known for early customer value prediction. ONAR will merge Retina.ai with its Cortex predictive analytics engine, enhancing its ability to forecast customer lifetime value (CLV), churn, and campaign ROI before ad spend. Used by brands like Unilever and Dollar Shave Club, Retina.ai strengthens ONAR’s SaaS offerings, unlocks cross-sell potential, and further integrates real-time data insights across its portfolio. Financial terms of the deal were not disclosed. To view the full press release, visit: https://ibn.fm/3I14d About ONAR ONAR…

ThursdayJul 17, 2025 9:46 am

AINewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Initiated with Buy Rating and $8 Price Target by Litchfield Hills Research

Safe Pro Group (NASDAQ: SPAI), a developer of AI-powered drone imagery solutions for defense and security applications, has been initiated with a Buy rating and $8 price target by Litchfield Hills Research. Analyst Theodore R. O’Neill cited SPAI’s patented mine detection technology—proven in Ukraine—as a 21st-century answer to outdated demining methods. The company’s SpotlightAI(TM) platform, capable of detecting threats in under 0.2 seconds, operates via cloud or edge computing and has already processed over 1.6 million drone images. The company is further supported by strong intellectual property protections and growing demand from global humanitarian and military efforts. SPAI’s diverse operating…

WednesdayJul 16, 2025 12:23 pm

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress

Lantern Pharma (NASDAQ: LTRN), a biotech company leveraging its RADR(R) AI platform to accelerate precision oncology drug development, has engaged IBN to lead its corporate communications strategy. With clinical programs targeting lung, brain, breast, and blood cancers—including three AI-guided candidates and a CNS-focused subsidiary—Lantern is advancing multiple FDA-designated therapies in active trials. The partnership with IBN aims to expand investor awareness as Lantern pursues key milestones across its data-driven, biomarker-informed pipeline. To view the full press release, visit https://ibn.fm/Yflb4 About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery…

TuesdayJul 15, 2025 12:50 pm

AINewsBreaks – BluSky AI Inc. (OTC: BSAI) Partners With Data Specialties Inc. to Accelerate Modular AI Data Center Deployment

BluSky AI (OTC: BSAI), a leader in modular AI data infrastructure, announced a strategic partnership with Data Specialties Inc. (DSI) to supply pre-manufactured modular data centers for its SkyMod platform. DSI, based in Buena Park, California, brings over 30 years of mission-critical data center expertise, enabling BluSky to rapidly deploy its SkyMod One (1.0 MW) and SkyMod XL (1.7 MW) units nationwide. The collaboration will support BluSky AI’s goal of exceeding 100 MW of operational capacity within 24 months, delivering scalable, high-performance compute environments for AI developers, enterprises and research institutions. To view the full press release, visit https://ibn.fm/CNFrG About…

TuesdayJul 15, 2025 11:20 am

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications. To…

AINewsWire provides insights in the emerging sector of Artificial Intelligence.

Contact us: (512) 354-7000

Breaks Categories: News